Aptar Pharma partners with CHI to commercialize Quattrii DPI platform

Aptar Pharma entered an exclusive collaboration agreement with Cambridge Healthcare Innovations (CHI) to lead the commercialization and promotion of the Quattrii Dry Powder Inhaler platform. Aptar will provide support for commercial manufacture and integration of its pharmaceutical services.

“Aptar Pharma today announced that it has entered into an exclusive collaboration agreement with Cambridge Healthcare Innovations (CHI) to lead the commercialization and promotion of its Quattrii Dry Powder Inhaler (DPI) platform.”aptar.com

• 1 source
• aptar.comAptar Pharma to Commercialize Quattrii Dry Powder Inhaler PlatformCiara JacksonNov 7, 2024

Summarized from public sources; check the original articles before acting on it.